中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

1331 records (took 0.049 seconds)

    METHODS AND COMPOSITIONS FOR PRODUCING A CELL EXPRESSING A T CELL RECEPTOR
    62.
    发明申请
    METHODS AND COMPOSITIONS FOR PRODUCING A CELL EXPRESSING A T CELL RECEPTOR 审中-公开
    用于产生细胞表达T细胞受体的方法和组合物

    公开(公告)号：WO2015113140A1

    公开(公告)日：2015-08-06

    申请号：PCT/CA2015/000049

    申请日：2015-01-28

    Applicant: UNIVERSITY HEALTH NETWORK

    Inventor： HIRANO, Naoto ,  NAKATSUGAWA, Munehide ,  OCHI, Toshiki

    IPC: C07K14/725 ,  A61K38/17 ,  C12N15/09 ,  C12N15/12 ,  C12N5/10 ,  C12P21/02

    CPC classification number: C07K14/7051 ,  A61K38/00 ,  C12N15/1037 ,  C12N15/1055

    Abstract: Provided is a method for determining a TCR polypeptide chain that can form a TCR specific for a peptide of interest. Also provided are methods and compositions for producing a cell expressing a T cell receptor (TCR) specific for a peptide of interest, methods and compositions for producing a TCR chain nucleic acid and/or pair of TCR chain polypeptides and/or nucleic acids encoding a TCR, a cell population comprising the cell harboring the nucleic acids encoding a TCR obtained by said method, and a method for treating a disorder comprising administering to the subject said cell population.

    Abstract translation: 本发明提供了一种确定可形成感兴趣肽特异性TCR的TCR多肽链的方法。 还提供了用于产生表达对感兴趣的肽特异性的T细胞受体（TCR）的细胞的方法和组合物，用于产生TCR链核酸和/或一对TCR链多肽和/或编码 TCR，包含携带编码通过所述方法获得的TCR的核酸的细胞的细胞群，以及用于治疗病症的方法，包括向受试者施用所述细胞群体。

    ANTIBODIES TO TOSO
    63.
    发明申请
    ANTIBODIES TO TOSO 审中-公开
    TOSO抗体

    公开(公告)号：WO2015000059A1

    公开(公告)日：2015-01-08

    申请号：PCT/CA2014/000537

    申请日：2014-07-02

    Applicant: UNIVERSITY HEALTH NETWORK

    Inventor： MAK, Tak, W. ,  LAI, Xiuqiu ,  TUSCHE, Michael, W.

    IPC: C07K16/28 ,  A61K39/395 ,  C07K16/46 ,  C12N15/13 ,  C12N15/63 ,  C12P21/08

    CPC classification number: C07K16/2803 ,  C07K2317/622

    Abstract: The present invention provides methods and compositions for modulating Toso activity and treating diseases and disorders in which Toso is implicated. Such methods and compositions include the use of one or more antibodies that bind to a Toso protein or to a ligand of a Toso protein.

    Abstract translation: 本发明提供了用于调节Toso活性并治疗涉及Toso的疾病和病症的方法和组合物。 这样的方法和组合物包括使用结合Toso蛋白质或Toso蛋白质配体的一种或多种抗体。

    CANCER BIOMARKERS AND METHODS OF USE
    68.
    发明申请
    CANCER BIOMARKERS AND METHODS OF USE 审中-公开
    癌症生物标志物和使用方法

    公开(公告)号：WO2013134860A1

    公开(公告)日：2013-09-19

    申请号：PCT/CA2013/000248

    申请日：2013-03-15

    Applicant: UNIVERSITY HEALTH NETWORK

    Inventor： DIAMANDIS, Eleftherios P. ,  PRASSAS, Ioannis ,  MAKAWITA, Shalini ,  CHRYSTOJA, Caitlin ,  KOSANAM, Hari, M.

    IPC: G01N33/48 ,  C12Q1/68 ,  G01N33/574 ,  C40B30/00

    CPC classification number: G01N33/57484 ,  G01N33/57419 ,  G01N33/57423 ,  G01N33/57434 ,  G01N33/57438 ,  G01N2333/705

    Abstract: A method of evaluating a probability a subject has a cancer, diagnosing a cancer and/or monitoring cancer progression comprising: a. measuring an amount of a biomarker selected from the group consisting of CUZD1 and/or LAMC2 and/or the group CUZD1, LAMC2, AQP8,, CELA2B, CELA3B,, CTRB1, CTRB2, GCG, IAPP, INS, KLK1, PNLIPRP1, PNLIPRP2, PPY, PRSS3, REG3G, SLC30A8, KLK3, NPY, PSCA, RLN1, SLC45A3, DSP, GP73, DSG2, CEACAM7, CLCA1, GPA33, LEFTY1, ZG16, IRX5, LAMP3, MFAP4, SCGB1A1, SFTPC, TMEM100, NPY, PSCA, RLN1 and/or SLC45A3 in a test sample from a subject with cancer; wherein the cancer is pancreas cancer if CUZD1, LAMC2, AQP8, CELA2B, CELA3B, CTRB1, CTRB2, GCG, IAPP, INS, KLK1, PNLIPRP1, PNLIPRP2, PPY, PRSS3, REG3G, SLC30A8, DSP, GP73 and/or DSG2 is selected; the cancer is colon cancer if CEACAM7, CLCA1, GPA33, LEFTY1 and/or ZG16 is selected, the cancer is lung cancer if IRX5, LAMP3, MFAP4, SCGB1A1, SFTPC and/or TMEM100 is selected; or the cancer is prostate cancer if NPY, PSCA, RLN1 and/or SLC45A3 is selected; b. comparing the measured amount to a control and detecting an increase in the amount of the biomarker compared to control; and c. identifying the subject as having or having an increased probability of having the cancer when an increase in the biomarker compared to control is detected.

    Abstract translation: 评估受试者患有癌症，诊断癌症和/或监测癌症进展的可能性的方法，包括：a。 测量从CUZD1和/或LAMC2和/或组CUZD1，LAMC2，AQP8，CELA2B，CELA3B，CTRB1，CTRB2，GCG，IAPP，INS，KLK1，PNLIPRP1，PNLIPRP2组成的组中选择的生物标志物的量， PPY，PRSS3，REG3G，SLC30A8，KLK3，NPY，PSCA，RLN1，SLC45A3，DSP，GP73，DSG2，CEACAM7，CLCA1，GPA33，LEFTY1，ZG16，IRX5，LAMP3，MFAP4，SCGB1A1，SFTPC，TMEM100，NPY，PSCA， 来自患有癌症的受试者的测试样品中的RLN1和/或SLC45A3; 其中如果选择了CUZD1，LAMC2，AQP8，CELA2B，CELA3B，CTRB1，CTRB2，GCG，IAPP，INS，KLK1，PNLIPRP1，PNLIPRP2，PPY，PRSS3，REG3G，SLC30A8，DSP，GP73和/或DSG2，则该癌症是胰腺癌 ; 如果选择CEACAM7，CLCA1，GPA33，LEFTY1和/或ZG16，癌症是结肠癌，如果选择了IRX5，LAMP3，MFAP4，SCGB1A1，SFTPC和/或TMEM100，则该癌是肺癌; 或者如果选择NPY，PSCA，RLN1和/或SLC45A3，则癌症是前列腺癌; 湾 将测量的量与对照相比较并检测与对照相比生物标志物的量的增加; 和c。 当检测到与对照相比生物标志物的增加时，将受试者识别为具有或具有增加的癌症概率的受试者。

    CANCER STEM CELL PROGNOSTICATION SYSTEMS (CPS)
    70.
    发明申请
    CANCER STEM CELL PROGNOSTICATION SYSTEMS (CPS) 审中-公开
    癌症干细胞预处理系统（CPS）

    公开(公告)号：WO2013056184A1

    公开(公告)日：2013-04-18

    申请号：PCT/US2012/060140

    申请日：2012-10-12

    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  UNIVERSITY HEALTH NETWORK

    Inventor： JAMIESON, Catriona, H. ,  FRAZER, Kelly, A. ,  BARRETT, Christian, L. ,  SADARANGANI, Anil ,  MARRA, Marco ,  MINDEN, Mark

    IPC: C12Q1/68 ,  G01N33/50 ,  G01N33/15

    CPC classification number: G01N33/5073 ,  C12Q1/6886 ,  C12Q2600/118

    Abstract: The disclosure herein provides compositions and methods for characterizing, recognizing or identifying a cancer stem cell or a leukemia stem cell. Also disclosed herein are compositions and methods for testing whether a drug, compound, diet, therapy or treatment is effective or efficacious for preventing, ameliorating, slowing the progress of, stopping or slowing the metastasis of, or for causing a full or partial remission of, a cancer, or a cancer stem cell, or a leukemia cancer stem cell. In addition, the disclosure provides "cancer stem cell prognostication systems" (CPSs), or multiplexed systems, or kits comprising e.g., a microarray or biochip or equivalent, or a collection, set or panel of oligonucleotides or primer pairs, or polymerase chain reaction (PCR) primer pairs, or equivalent, capable of identifying or characterizing part, substantially all or the whole (entire, complete) transcriptome expression pattern of a cancer stem cell.

    Abstract translation: 本文的公开内容提供用于表征，识别或鉴定癌症干细胞或白血病干细胞的组合物和方法。 本文还公开了用于测试药物，化合物，饮食，治疗或治疗是否有效或有效用于预防，改善，减缓转移的进展，停止或减缓转移或导致全部或部分缓解的组合物和方法 ，癌症或癌症干细胞，或白血病癌症干细胞。 此外，本公开提供了“癌症干细胞预后系统”（CPS）或多重系统或包含例如微阵列或生物芯片或等效物，或寡核苷酸或引物对的集合，组或聚合酶链反应的试剂盒 （PCR）引物对或等同物，其能够鉴定或表征癌症干细胞的部分，基本上全部或全部（完整的，完整的）转录组表达模式。

Patent Agency Ranking